CG Oncology, Inc. (CGON)
| Market Cap | 5.53B |
| Revenue (ttm) | 4.04M |
| Net Income (ttm) | -161.00M |
| Shares Out | 84.44M |
| EPS (ttm) | -2.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 497,607 |
| Open | 67.45 |
| Previous Close | 66.82 |
| Day's Range | 65.38 - 68.00 |
| 52-Week Range | 21.00 - 73.56 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 77.64 (+18.53%) |
| Earnings Date | May 8, 2026 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with... [Read more]
Financial Performance
In 2025, CG Oncology's revenue was $4.04 million, an increase of 254.70% compared to the previous year's $1.14 million. Losses were -$161.00 million, 82.9% more than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $77.64, which is an increase of 18.53% from the latest price.
News
CG Oncology Transcript: TD Cowen 46th Annual Health Care Conference
Credo demonstrates strong efficacy and durability in multiple bladder cancer settings, with a 75.5% CR rate in BOND-003 and promising adjuvant and combination data. Regulatory filings are underway, with commercial launch preparations targeting a concentrated market and leveraging a robust team.
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
IRVINE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the fourth quarter and year ended December 31, 2025, and provided business updat...
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating ...
CG Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted strong clinical progress for a novel bladder-sparing immunotherapy, with pivotal trials in both high-risk and intermediate-risk NMIBC nearing key data readouts. The therapy shows best-in-class efficacy, safety, and commercial readiness, with regulatory submissions and market expansion planned through 2027.
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
IRVINE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Announces New Board Member and Board Transition
- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical bi...
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The session highlighted strong two-year response and durability data for CReDO in BCG-unresponsive NMIBC, a robust regulatory and manufacturing strategy, and plans to establish CReDO as backbone therapy across multiple bladder cancer segments. Upcoming pivotal data and a solid cash position support future growth.
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's ca...
CG Oncology Transcript: Cantor Global Healthcare Conference 2025
Significant progress was reported in late-stage clinical trials for NMIBC, including strong 24-month efficacy data and accelerated trial enrollment. Regulatory and manufacturing strategies are focused on CMC readiness and streamlined administration, while commercial plans target unmet needs in high-volume centers.
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Ca...
CG Oncology Completes Enrollment in PIVOT-006
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompas...
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Ini...
CG Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025
Significant progress in non-muscle invasive bladder cancer with strong clinical data, streamlined administration, and a robust commercial strategy targeting high-volume accounts. BLA filing is on track for year-end, supported by a solid cash position and multiple upcoming data readouts.
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025
Cretostimogene demonstrated strong durability and tolerability in high-risk NMIBC, with 46% 12-month and 34% 24-month CR rates, and 97.3% cystectomy-free survival at 24 months. Regulatory filing is planned for H2 2025, and the company is well-financed through 2028.
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signa...
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
CG Oncology Transcript: Study Update
Phase 3 data for cretostimogene in high-risk BCG-unresponsive non-muscle-invasive bladder cancer show a 75.5% complete response rate, class-leading durability, and a favorable safety profile. The therapy is easily administered, with ongoing trials in additional settings and combinations.
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
CG Oncology Transcript: TD Cowen 45th Annual Healthcare Conference
Focused on bladder-sparing therapies for NMIBC, the program shows strong efficacy, durability, and safety, with a robust regulatory and commercial strategy targeting a large, concentrated U.S. market. Multiple pivotal data readouts and a BLA submission are expected later this year.
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...